Legend Biotech's GAAP loss for 3 months of 2022 was $41.087 million, down 49.2% from $80.899 million in the previous year. Revenue tripled to $40.827 million from $13.682 million a year earlier.

European Commission has granted conditional approval for CARVYKTI by Legend Biotech. The drug is intended to treat adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and have demonstrated disease progression on the last therapy. The drug was approved by the FDA in February of this year.

Legend Biotech's GAAP loss for 2021 was $386.209 million, up 27.3% from $303.477 million in the previous year. Revenue increased 18.7% to $89.792 million from $75.676 million a year earlier.

Legend Biotech's GAAP loss for 9M 2021 was $297.875 million, up 21.3% from $245.65 million in the prior year. Revenue increased 45.6% to $50.797 million from $34.893 million a year earlier.